Sign in

RVRC on OTC

Revium Rx.

Revium Rx. is an American pharmaceutical preparations company, incorporated in Delaware.1 It is headquartered in New York, New York.1 Its shares trade on OTC under the symbol RVRC.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with another stock.

  • TickerRVRC on OTC1
  • IndustryPharmaceutical Preparations1
  • HeadquartersNew York, New York1
  • Incorporated inDE2
  • Business addressC/O Aboudi Legal Group Pllc, 745 5Th Ave, Suite 500, New York, Ny 101512
  • Filer categoryNon-accelerated filer, Smaller reporting company, Emerging growth company2

See how the biggest companies compare on our leaderboards

(Comirnaty): Used LNPs to encapsulate and deliver mRNA encoding the SARS-CoV-2 spike protein [5].3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Every line of the income statement as filed: the last 1 fiscal year, latest first.4

Period ending2025-12-31
Tax expenses$358.0K
Net loss and comprehensive loss$13.4M
Basic net loss per share to shareholders of the parent Company (in Dollars per share)-$0.22
Diluted net loss per share to shareholders of the parent Company (in Dollars per share)-$0.22
Weighted average number of ordinary shares used in computing basic net loss per share (in Shares)60.7M shares
Weighted average number of ordinary shares used in computing diluted net loss per share (in Shares)60.7M shares

Compare Revium Rx. with another company

What it owns

What Revium Rx. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net$10.0K4 Dec 31, 2025$9.0K4 Dec 31, 2024+11.1%
Operating-lease assets (leased space)$119.0K4 Dec 31, 2025

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$1.7M4 Dec 31, 2025$3.3M4 Dec 31, 2024−48.7%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$2.6M4 Dec 31, 2025$11.4M4 Dec 31, 2024−77.4%
Intangible assets, net (excluding goodwill)$2.5M4 Dec 31, 2025$3.3M4 Dec 31, 2024−25.3%
Indefinite-lived intangibles (excluding goodwill)$2.5M4 Dec 31, 2025$3.3M4 Dec 31, 2024−25.3%

Properties, in its own words

Our principal executive offices are located at Azrieli Business Center, 8 Mediant HaYehudim, Herzliya, Israel, and our phone number is 1 800 519-1687. Our website is www.reviumrx.com. Information contained in, or that can be accessed through, our website is not incorporated by reference into this report, and you should not consider information on our website to be part of this report.

We currently own no real property. We believe our facilities are adequate for our current and planned business operations.

Item 2 of the 10-K filed Mar 31, 2026.3

Timeline

  1. Jun 22, 20268-K Executive or director change7
  2. Jun 1, 20268-K Executive or director change8
  3. Apr 20, 20268-K Executive or director change9

Filings

13 filings to the SEC since October 2021: 1 annual reports, 2 quarterly reports, 3 major events, 7 other. The latest 13:

  1. Aug 13, 202610-Q QUARTERLY REPORT EDGAR
  2. Jun 22, 20268-K CURRENT REPORT EDGAR
  3. Jun 1, 20268-K CURRENT REPORT EDGAR
  4. May 14, 202610-Q QUARTERLY REPORT EDGAR
  5. Apr 20, 20268-K CURRENT REPORT EDGAR
  6. Mar 31, 202610-K ANNUAL REPORT EDGAR
  7. Jan 30, 2026EFFECT EDGAR
  8. Jan 28, 2026S-1/A AMENDMENT NO. 5 TO FORM S-1 EDGAR
  9. Jan 16, 2026S-1/A AMENDMENT NO. 4 TO FORM S-1 EDGAR
  10. Dec 12, 2025S-1/A AMENDMENT NO. 3 TO FORM S-1 EDGAR
  11. Oct 3, 2025S-1/A AMENDMENT NO. 2 TO FORM S-1 EDGAR
  12. Aug 13, 2025S-1/A AMENDMENT NO. 1 TO FORM S-1 EDGAR
  13. Feb 14, 2025S-1 REGISTRATION STATEMENT EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

SEC filer profile

How Revium Rx. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARRevium Rx.1
  • CIK0001839140
  • Employer ID (EIN)84-45166763
  • Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; not a shell company3
  • Incorporated inNevada3
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business addressC/O Aboudi Legal Group Pllc, 745 5Th Ave, Suite 500, New York, NY 101511
  • Phone64676842851
  • Shares outstanding60,729,100 as of Aug 13, 20265
  • Public float$14.3M as of Jun 30, 20253
  • AuditorZiv Haft, Tel-Aviv, Israel PCAOB ID 1185; no auditor attestation of internal control over financial reporting3
  • On EDGAR sinceFeb 14, 20251
  • Filings13 in all: S-1/A (5), 8-K (3), 10-Q (2), 10-K (1), EFFECT (1), S-1 (1)1
  • Latest filingsAnnual report (10-K) Mar 31, 2026
    Quarterly report (10-Q) Aug 13, 2026
    Latest 8-K (8-K) Jun 22, 2026

Risk factors and legal proceedings

The risks Revium Rx. names in Item 1A of its 10-K filed Mar 31, 2026: 42 risks under these headings, as written.3

  • Risks Related to our Business and Financial Condition
  • We have a history of losses and may never achieve profitability.
  • We will need substantial additional funding to realize our business plan, due to a number of factors, some of which are beyond our control. We may not be able to raise capital when needed, if at all, which would force us to delay, reduce or eliminate our product development programs or commercialization efforts and could cause our business to fail.
  • There is substantial doubt about our ability to continue as a going concern.
  • We anticipate that we can successfully develop the acquired business of LipoVation resulting from the closing of the Share Exchange. However, if we fail to comply with LipoVation’s contractual obligations under the Yissum License Agreements, we could lose license rights that may be necessary for developing our Nano-Liposomal Particles (NLP)-based medicines based therapeutic products.
  • Uncertainty surrounding our option to obtain an exclusive license to the Nano-Candesartan program, including a disagreement with Yissum regarding the status and timing of the option exercise period, could limit our development pipeline and adversely affect our business.
  • Our Chief Financial Officer may face competing demands on his time and attention.
  • We are dependent upon our officers and directors and their loss, or a reduction in the amount of time they can dedicate to our initial business combination, could adversely affect our ability to operate.
  • The competitive landscape is highly dynamic, with continuous advancements in science and technology leading to the emergence of novel therapeutic modalities. Regulatory approvals, strategic partnerships, and market adoption of competing therapies could significantly impact the commercial potential of our novel product candidates.
  • We are increasingly dependent on information technology, and our systems and infrastructure face certain risks, including cybersecurity and data leakage risks.
  • Risks Relating to the Development and Commercialization of our Drug Candidates and Regulatory Approval
  • The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and even if we obtain approval for a product candidate in one country or jurisdiction, we may never obtain approval for or commercialize it in any other jurisdiction, which would limit our ability to realize our full market potential.
The other 31 risks
  • Additional time and costs may be required to obtain marketing authorizations for the ARB-based product candidate that we develop as part of a combination therapy.
  • We may seek expedited development or approval pathways for certain of our product candidates, but there is no assurance that such pathways will be granted or will accelerate clinical development or approval.
  • Our LNP-based product candidates in Combination with Other Therapies may result in unexpected adverse effects, which could delay, limit, or prevent their development and commercialization.
  • Conducting clinical trials for systemic antibiotics involves inherent risks, safety concerns, and regulatory requirements for demonstrating efficacy in treating bacterial infections.
  • We face Clinical Trial and other Challenges in Connection with the development of Product Candidates.
  • We may not be successful in establishing and maintaining development and commercialization collaborations, which could adversely affect our ability to develop certain of our product candidates and our financial condition and operating results.
  • The success of our business operations is dependent on our ability to successfully develop our products and to complete clinical programs. We cannot assure you that we will successfully develop any products, or if we do, that they will be commercially successful.
  • Risks Related to Protection of our Intellectual Property
  • Our pending patent applications may not result in issued patents, and any patents that may be granted could include only limited claims. As a result, our intellectual property protection may be weaker than anticipated, which could make it more difficult for us to establish or maintain a competitive position.
  • Our inability to protect our trademarks, patents and trade secrets may prevent us from successfully marketing our products and competing effectively.
  • The patenting process, enforcement of issued patents, and defense against claims of infringement are inherently risky.
  • We may be unable to secure new patent protection for our LPLT-based immunization platform approach through additional patent applications, or may receive only partial claim approvals, which could limit the scope of intellectual property protection.
  • We may be subject to legal claims against us or claims by us which could have a significant impact on our resulting financial performance.
  • Risks Relating to our Operations in Israel
  • Our principal executive offices, most of our research and development activities and other significant operations are located in Israel, and, therefore, our results may be adversely affected by political, economic and military instability in Israel, including Israel’s multi-front war with terrorist groups in neigh boring countries, such as Hezbollah in Lebanon and Hamas in the Gaza Strip, and state actors such as Iran, and Israel’s response thereto
  • Our operations and the operations of our contractors in Israel may be disrupted as a result of the obligation of Israeli citizens to perform military service.
  • Our future sales may be adversely affected by boycotts of Israel.
  • There may be limitations on transfers of our technology.
  • Risks Relating to our Common Stock
  • Our principal stockholders can significantly influence or control matters requiring a shareholder vote and other stockholders may not have the ability to influence corporate transactions. The sale of a large number of shares of Common Stock by our principal stockholders could depress the market price of our common stock.
  • Our Common Stock is considered a “penny stock,” and any investment in our shares is considered to be a high-risk investment and is subject to restrictions on marketability. “Penny Stock” rules may make buying or selling our Common Stock difficult. Limitations upon Broker-Dealers Effecting Transactions in “Penny Stocks”.
  • The market price of our Common Stock may fluctuate significantly in the future.
  • The requirements of becoming an SEC reporting public company may strain our resources, divert management’s attention and affect our ability to attract and retain executive management and qualified board members.
  • Revium is an emerging growth company within the meaning of the Securities Act and may take advantage of certain reduced reporting requirements.
  • We must implement additional and expensive procedures and controls in order to grow our business and organization and to satisfy new reporting requirements, which will increase our costs and require additional management resources.
  • The market price for our Common Stock may be particularly volatile given our status as a relatively unknown company, with a lack of profits, which could lead to wide fluctuations in our share price. You may be unable to sell your Common Stock at or above your purchase price, which may result in substantial losses to you.
  • Our future results may vary significantly, which may adversely affect the price of our Common Stock.
  • The offer and sale of the Units by the Company in this Offering, the recent consummation of the Share Exchange with LipoVation, other acquisitions, and financing transactions could significantly dilute shareholder ownership and may cause it to become more susceptible to adverse economic events.
  • Our internal controls may be inadequate, which could cause our financial reporting to be unreliable and lead to misinformation being disseminated to the public.
  • The costs of being an SEC-reporting public company could result in us being unable to continue as a going concern.
  • Our Common Stock is trading on the OTCID Market, a securities quotation system. An active, liquid trading market for our Common Stock may not develop or be sustained. If and when an active market develops, the price of our common stock may be volatile.
  • The trading market for our Common Stock will be influenced by the research and reports that equity research analysts publish about us and our business.
  • We do not intend to pay dividends on our Common Stock.
  • Nevada law and provisions in our Articles of Incorporation and our new Nevada bylaws could make a merger, tender offer or proxy contest difficult, thereby depressing the market price of our Common Stock.

Legal proceedings

From time to time, we are subject to ordinary routine litigation incidental to our normal business operations. We are not currently a party to any material legal proceedings.

The opening of Item 3, Legal Proceedings.3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9